Who owns Adaptimmune Therapeutics?
- Ticker: ADAP
- CUSIP Number: 00653a107
Tip: Access positions for across all investors
Analyze quarterly positions in Adaptimmune Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Adaptimmune Therapeutics stock
Who bought or sold Adaptimmune Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| NEA Management Company | 17M | $14M | 0% | Dec 2023 |
|
| Baillie Gifford & Co | 16M | $13M | -7% | Dec 2023 |
|
| Long Focus Capital Management | 12M | $9.6M | 10% | Dec 2023 |
|
| Baker Bros. Advisors | 11M | $8.7M | 0% | Dec 2023 |
|
| Partner Fund Management | 10M | $8.3M | 0% | Dec 2023 |
|
| Bank of America Corporation | 4.7M | $3.7M | 0% | Dec 2023 |
|
| Tang Capital Management | 4.4M | $3.5M | -15% | Dec 2023 |
|
| Citadel Advisors | 3.4M | $2.7M | -4% | Dec 2023 |
|
| Syncona Portfolio | 1.4M | $1.1M | 0% | Dec 2023 |
|
| Jpmorgan Chase & Co | 928k | $736k | -10% | Dec 2023 |
|
| Redmile Group | 716k | $568k | 0% | Dec 2023 |
|
| GSA Capital Partners | 509k | $403k | 100% | Dec 2023 |
|
| Acuitas Investments | 480k | $381k | 0% | Dec 2023 |
|
| Millennium Management | 441k | $350k | 47% | Dec 2023 |
|
| DAFNA Capital Management | 351k | $278k | 0% | Dec 2023 |
|
| Key Client Fiduciary Advisors | 269k | $425k | -20% | Mar 2024 |
|
| Harbor Capital Advisors | 148k | $117k | 10% | Dec 2023 |
|
| Marquette Asset Management | 99k | $78k | -1% | Dec 2023 |
|
| Jane Street | 98k | $77k | 100% | Dec 2023 |
|
| Hrt Financial | 60k | $47k | 100% | Dec 2023 |
|
| Two Sigma Advisers | 60k | $48k | -7% | Dec 2023 |
|
| Wells Fargo & Company | 56k | $45k | 3% | Dec 2023 |
|
| Barclays | 50k | $40k | 0% | Dec 2023 |
|
| Cubist Systematic Strategies | 35k | $27k | 100% | Dec 2023 |
|
| Wealth Enhancement Advisory Services | 32k | $51k | 0% | Mar 2024 |
|
| Main Street Financial Solutions | 31k | $25k | 0% | Dec 2023 |
|
| CSS | 31k | $24k | -66% | Dec 2023 |
|
| DLK Investment Management | 31k | $48k | 0% | Mar 2024 |
|
| Massey, Quick & Co | 30k | $24k | 100% | Dec 2023 |
|
| Janney Montgomery Scott | 30k | $24k | 0% | Dec 2023 |
|
| Prosperity Wealth Management | 29k | $23k | -7% | Dec 2023 |
|
| Virtu Financial | 28k | $23k | 100% | Dec 2023 |
|
| X-Square Capital | 27k | $22k | 2% | Dec 2023 |
|
| Stifel Financial | 27k | $22k | -9% | Dec 2023 |
|
| Hsbc Holdings | 27k | $19k | 2% | Dec 2023 |
|
| UBS Group | 25k | $20k | -13% | Dec 2023 |
|
| Newman Dignan & Sheerar | 23k | $18k | 100% | Dec 2023 |
|
| Hunter Associates | 23k | $19k | -4% | Dec 2023 |
|
| Captrust Financial Advisors | 17k | $14k | -21% | Dec 2023 |
|
| Commonwealth Equity Services | 17k | $13k | -47% | Dec 2023 |
|
| Goldman Sachs Group | 16k | $13k | -72% | Dec 2023 |
|
| Columbia Advisory Partners | 16k | $25k | 100% | Mar 2024 |
|
| Ballentine Partners | 15k | $23k | 100% | Mar 2024 |
|
| Procyon Private Wealth Partners | 13k | $21k | 100% | Mar 2024 |
|
| Raymond James & Associates | 10k | $8.1k | -1% | Dec 2023 |
|
| Advisor Group Holdings | 6.3k | $5.0k | -40% | Dec 2023 |
|
| Global Retirement Partners | 6.0k | $4.3k | 0% | Dec 2023 |
|
| Rhumbline Advisers | 5.9k | $4.7k | 6% | Dec 2023 |
|
| Lindbrook Capital | 4.6k | $3.7k | 0% | Dec 2023 |
|
| Lazard Asset Management | 4.2k | $0 | -4% | Dec 2023 |
|
| Wetzel Investment Advisors | 3.0k | $2.0k | 100% | Dec 2023 |
|
| Bnp Paribas Arbitrage, Snc | 2.2k | $1.7k | -47% | Dec 2023 |
|
| Cutler | 1.4k | $1.0k | -7% | Dec 2023 |
|
| Sandy Spring Bank | 1.1k | $832.965000 | 0% | Dec 2023 |
|
| Royal Bank of Canada | 592.00 | $0 | -97% | Dec 2023 |
|
| Carmichael Hill & Associates | 525.00 | $417.007500 | 0% | Dec 2023 |
|
| Simplex Trading | 300.00 | $0 | 100% | Dec 2023 |
|
| HighMark Wealth Management | 287.00 | $227.992800 | 0% | Dec 2023 |
|
| Advisory Services Network | 125.00 | $99.000000 | 100% | Dec 2023 |
|
| Investors Research Corp | 100.00 | $79.000000 | 0% | Dec 2023 |
|
Who sold out of Adaptimmune Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Artal Group | Sep 2023 | 1.1M | $884k |
| Citigroup | Sep 2023 | 582k | $454k |
| Endurant Capital Management | Sep 2023 | 312k | $243k |
| Simplify Asset Management | Sep 2023 | 150k | $117k |
| Black Maple Capital Management | Sep 2023 | 70k | $55k |
| Two Sigma Investments | Sep 2023 | 60k | $47k |
| Douglas Lane & Associates | Dec 2023 | 11k | $8.7k |
| Bayesian Capital Management | Sep 2023 | 11k | $8.2k |
| China Universal Asset Management | Sep 2023 | 5.3k | $4.0k |
| Us Bancorp | Sep 2023 | 1.1k | $825.028400 |
| Daiwa Securities Group | Sep 2023 | 469.00 | $0 |